Skip to main content
EDIT logo

EDIT · Editas Medicine, Inc.

Track EDIT — free
$2.82 +0.01 (+0.36%) At close · Aug 14
Market Cap
$433.10M
Shares
153.58M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Gilmore O’Neill $2,353,655
Linda Burkly $1,176,389
Amy Parison $821,655
Fiscal 2024
Executive Total
Gilmore O’Neill $5,126,868
Erick Lucera $1,809,321
Baisong Mei $821,402
Fiscal 2023
Executive Total
Gilmore O’Neill $2,392,309
Erick Lucera $2,215,616
Michelle Robertson $1,577,496
Linda Burkly $1,537,048
Bruce Eaton $1,305,388
Baisong Mei $1,141,405
Fiscal 2022
Executive Total
Gilmore O’Neill $9,058,900
Michelle Robertson $3,422,086
Baisong Mei $3,010,747
Bruce Eaton $2,735,748
Fiscal 2021
Executive Total
Michelle Robertson $2,247,017
Bruce Eaton $1,840,813
Fiscal 2019
Executive Total
Cynthia Collins $14,489,736
Judith Abrams $2,825,252
Charles Albright Ph.D $1,996,323
Vic Myer $1,608,717
Eric Ek $1,139,984
Katrine S. Bosley $661,240
Andrew A. F. Hack $70,187
Fiscal 2018
Executive Total
Katrine S. Bosley $7,989,383
Andrew A. F. Hack $2,999,578
Vic Myer $2,455,739
Charles Albright Ph.D $2,387,899
Fiscal 2017
Executive Total
Katrine S. Bosley $6,091,500
Andrew A. F. Hack $2,051,456
Charles Albright Ph.D $1,266,635

Executive changes

Person Change Filed
Patrick Ellinor, M.D., Ph.D. Appointed 2026-08-05
Elliott Levy, M.D. Resigned 2026-08-05
David Scadden, M.D. Appointed 2025-06-02
Jessica Hopfield, Ph.D. Appointed 2025-06-02
Amy Parison Appointed 2025-03-20
Erick Lucera Resigned 2025-03-20
Jessica Hopfield Appointed 2024-12-12
Emma Reeve Resigned 2024-12-12
Meeta Chatterjee Resigned 2024-12-12
Akshay Vaishnaw Resigned 2024-06-27
Erick J. Lucera Appointed 2023-05-17
Elliot Levy, M.D. Appointed 2023-04-13
Gilmore O'Neill, M.B., M.M.Sc. Appointed 2022-04-14
Gilmore O'Neill, M.B., M.M.Sc. Appointed 2022-04-14
Key facts CIK 1650664 CUSIP 28106W103 13F (30d) 226 filings 201 filers Visit website Investor relations